ACG
MRVI icon

Anchorage Capital Group’s Maravai LifeSciences MRVI Stock Holding History

Anchorage Capital Group’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-150,000
Closed -$5.35M – 27
2021
Q1 		$5.35M Hold
150,000
– – 0.27% 19
2020
Q4 		$4.21M Buy
+150,000
New +$4.18M 0.21% 20

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Anchorage Capital Group's MRVI Position: Q2 2021 in Review

Anchorage Capital Group sold out of Maravai LifeSciences (MRVI) in Q2 2021, closing a stake of 150,000 shares — an estimated $5.35M sold.

Anchorage Capital Group first reported a position in MRVI in Q4 2020 and held it in 2 quarters. The position peaked at $5.35M in Q1 2021. 196 funds tracked by Wall St. Rank hold MRVI as of Q2 2021.

  • Anchorage Capital Group reported no remaining Maravai LifeSciences position as of Q2 2021 after selling out during the quarter.
  • Anchorage Capital Group sold 150,000 Maravai LifeSciences shares in Q2 2021, an estimated $5.35M.
  • Anchorage Capital Group first reported a position in Maravai LifeSciences in Q4 2020 and held it in 2 quarters.
  • Anchorage Capital Group's Maravai LifeSciences position peaked at $5.35M in Q1 2021.
  • 196 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2021.

Based on Anchorage Capital Group's 13F filing for Q2 2021, filed 16 Aug 2021.